Flyrcado : A Breakthrough In Cardiac PET Imaging For Coronary Artery Disease

In a landmark advancement for nuclear cardiology, GE HealthCare has launched Flyrcado™ (flurpiridaz F 18), the first FDA-approved unit-dose positron emission tomography (PET) myocardial perfusion imaging (MPI) agent for detecting coronary artery disease (CAD). Approved in September 2024 and commercially available in select U.S. markets since early 2025, Flyrcado promises higher diagnostic accuracy, broader accessibility, and enhanced clinical flexibility compared to traditional SPECT MPI. This innovation marks the first new cardiac perfusion tracer in nearly 30 years, addressing long-standing limitations in cardiac imaging. With its 109-minute half-life—ten times longer than conventional PET tracers—Flyrcado enables centralized production and nationwide distribution, eliminating the need for on-site cyclotrons and expanding access to community hospitals and smaller healthcare systems. More details at : https://dengyuemed.com/news/flyrcado-a-breakthrough-in-cardiac-pet-imaging/